000			01668na a2200301 4500
999			_c818 _d818
003			PC818
005			20181031130530.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aPablo Gafas, Alicia de _91636 _eNeumología
245	0	0	_aRecommendations on the use of everolimus in lung transplantation. _h[artículo]
260			_bTransplantation Reviews, _c2013
300			_a27(1):9-16.
500			_aFormato Vancouver: De Pablo A, Santos F, Solé A, Borro JM, Cifrian JM, Laporta R et al. Recommendations on the use of everolimus in lung transplantation. Transplant Rev (Orlando). 2013 Jan;27(1):9-16.
501			_aPMID: 23276646
504			_aContiene 89 referencias
520			_aThe antiproliferative effect of everolimus provides a therapeutic option in the immunosuppression therapy of lung transplantation, by reducing both the risk of acute rejection and the process of progressive fibrosis that determines chronic graft rejection. However, few data on the use of everolimus in lung transplantation have been published to date, and the specific indications of the drug, along with the most adequate time for its introduction or dosing, have not been defined yet. The aim of this article is to propose recommendations for the use of everolimus in lung transplant recipients, including indications, dosing schedules and the use of concomitant immunosuppression. This consensus document has been developed by experts of all the Spanish lung transplant groups from the review of the existing literature and the clinical experience.
710			_988 _aServicio de Neumología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/8/pc818.pdf _ySolicitar documento
942			_n0 _2ddc _cART